Senesco Technologies reported the treatment of the first patient at the Company’s newly opened clinical-trial site at Seattle Cancer Care Alliance (SCCA). This patient is part of Senesco’s Phase 1b/2a clinical study of its ...
Tags: Senesco, Clinical Trial
Clinical-stage biopharmaceutical company Pharmacyclics' new drug application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been accepted by the US FDA for two B-cell malignancy indications. ...
Tags: Solvay Group, Medicine
Genentech, a member of the Roche Group, has obtained FDA priority review status for Obinutuzumab (GA101) to treat previously untreated chronic lymphocytic leukemia (CLL). The FDA has also accepted the company's biologics license ...
Tags: Genentech, FDA Priority
Diagnovus has announced the launch of a gene expression assay, ENGAUGE-cancer-DLBCL, designed for use in patients with diffuse large B-cell lymphoma (DLBCL). The assay, which combines patients International Prognostic Index (IPI) score ...
Tags: Diagnovus, B-Cell lymphoma, Medicine
Cell Therapeutics (CTI) has announced the European launch of Pixuvri for the treatment of adult patients with multiply relapsed or refractory aggressive non-hodgkin B-cell lymphoma. The company initiated the launch with entry into Sweden, ...
Tags: Cell Therapeutics, Pixuvri, NHL, B-cell lymphoma